96PD - Clinical activity, safety and subpopulation response analysis of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pt) with non-small cell lu...

Date 28 March 2014
Event ELCC 2014
Session Poster Discussion 2
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Presenter Julie Brahmer
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors J.R. Brahmer1, L. Horn2, S.J. Antonia3, D.R. Spigel4, L.V. Sequist5, C.M. Ahlers6, V. Sankar6, G. Kollia6, S. Gettinger7
  • 1Associate Professor Of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 21287 - Baltimore/US
  • 2Department Of Medicine, Vanderbilt-Ingram Cancer Center, Nashville/US
  • 3Department Of Interdisciplinary Oncology And The Immunology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa/US
  • 4Hematology/oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville/US
  • 5Hematology/oncology, Massachusetts General Hospital, Boston/US
  • 6Nivolumab, Bristol-Myers Squibb, Princeton/US
  • 7Medical Oncology, Yale Cancer Center, New Haven/US

 

Abstract

Treatment with nivolumab, a fully human IgG4, PD-1 immune checkpoint inhibitor antibody resulted in durable objective responses (ORs) and prolonged stable disease in pts with advanced NSCLC in a phase 1 study (CA209-003; NCT00730639) (Topalian S, et al. N Engl J Med. 2012;366:2443-54). We report long-term safety, efficacy, updated survival outcomes and clinical activity in subpopulations of the NSCLC cohort.